Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab prophylaxis in immunocompromised Japanese infants and young children
jRCT2080221638Phase 3
- Sponsor
- Abbott Laboratories
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palivizumab in respiratory syncytial virus disease (RSV), sponsored by Abbott Laboratories.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080221638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221638.